Pituitary adenylate cyclase activating peptide and vasoactive intestinal polypeptide: differentiation effects on human neuroblastoma NB-OK-1 cells.
Pituitary adenylate cyclase activating peptide-38 (PACAP-38), PACAP-27 and vasoactive intestinal polypeptide (VIP) increased intracellular cAMP content in human neuroblastoma NB-OK-1 cells transiently. PACAP and VIP also arrested cell growth and induced morphological differentiation, which lasted for 24 h in spite of removal of PACAP-38 and PACAP-27. The order of potencies for the neurite outgrowth and the arrest of cell growth is PACAP-38 > PACAP-27 > VIP. The results suggest the possibility that these neuropeptides are new candidates for differentiation activity.
Hoshino
M
M
Laboratory of Environmental Metabolism, Graduate School of Nutritional and Environmental Sciences, University of Shizuoka, Japan.
Li
M
M
Zheng
L Q
LQ
Suzuki
M
M
Mochizuki
T
T
Yanaihara
N
N
D002454:Cell Differentiation / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D002851:Chromatography, High Pressure Liquid; D000242:Cyclic AMP / Q000378:metabolism; D006801:Humans; D016501:Neurites / Q000187:drug effects / Q000648:ultrastructure; D009447:Neuroblastoma / Q000378:metabolism / Q000648:ultrastructure*; D009479:Neuropeptides / Q000494:pharmacology*; D018377:Neurotransmitter Agents / Q000494:pharmacology*; D051219:Pituitary Adenylate Cyclase-Activating Polypeptide; D014407:Tumor Cells, Cultured / Q000187:drug effects; D014660:Vasoactive Intestinal Peptide / Q000494:pharmacology*
C495401:ADCYAP1 protein, human; D009479:Neuropeptides; D018377:Neurotransmitter Agents; D051219:Pituitary Adenylate Cyclase-Activating Polypeptide; D014660:Vasoactive Intestinal Peptide; D000242:Cyclic AMP